What is Immunai?
Founded in 2018 and headquartered in New York City, Immunai operates at the intersection of artificial intelligence and immunology. The company develops advanced AI platforms designed to analyze the intricacies of the human immune system. This capability is crucial for accelerating drug discovery, developing personalized medicine, and advancing our understanding of various diseases. By leveraging sophisticated computational methods, Immunai aims to unlock new insights into immune responses, positioning itself as a key player in the rapidly evolving field of computational biology and health innovation.
How much funding has Immunai raised?
Immunai has raised a total of $295M across 3 funding rounds:
Angel/Seed
$20M
Series A
$60M
Series B
$215M
Angel/Seed (2020): $20M with participation from TLV Partners and Viola Group
Series A (2021): $60M, investors not publicly disclosed
Series B (2021): $215M supported by Alexandria Venture Investments, Talos, 8VC, and Koch Disruptive Technologies
Key Investors in Immunai
TLV Partners
TLV Partners is an Israeli venture capital firm that invests in early-stage startups, collaborating with innovative entrepreneurs to create category-defining companies. With over $1 billion under management, the firm focuses on exceptional teams that are poised to shape the future across various sectors, including AI, healthcare, and application security.
Viola Group
Viola Group is Israel's leading technology investment group, managing over $6 billion in assets. The firm supports Israeli entrepreneurs in building transformational technology companies through its multi-strategy investment approach. It operates several investment arms, including Viola Ventures, Viola Growth, Viola Credit, and Viola FinTech, catering to companies at various stages of development.
Alexandria Venture Investments
Alexandria Venture Investments is a venture capital firm that likely focuses on investing in companies within the life sciences and technology sectors, given its association with Alexandria Real Estate Equities, a major player in life science real estate.
What's next for Immunai?
The recent major strategic investment, coupled with the overall enterprise-level funding context, suggests Immunai is poised for significant scaling and expansion. This capital infusion is likely to fuel further research and development, enhance its AI platform's capabilities, and potentially broaden its market reach. The company's focus on the human immune system, a complex and vital area of biological research, positions it for substantial growth. Immunai's strategic direction will likely involve deepening its partnerships within the pharmaceutical and biotechnology sectors, aiming to translate its technological advancements into tangible therapeutic solutions and diagnostic tools.
See full Immunai company page
